Format

Send to

Choose Destination
Pharmacogenomics. 2019 Aug;20(13):927-929. doi: 10.2217/pgs-2019-0064.

TRK inhibitors: toward an era of agnostic targeted therapies in oncology.

Author information

1
Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.

KEYWORDS:

NTRK fusion; TRK inhibitors; entrectinib; larotrectinib; tumor agnostic

PMID:
31486737
DOI:
10.2217/pgs-2019-0064
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center